Affinage

SSX2

Protein SSX2 · UniProt Q16385

Length
188 aa
Mass
21.6 kDa
Annotated
2026-06-10
61 papers in source corpus 16 papers cited in narrative 16 extracted findings
Cross-family judge faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SSX2 is a nuclear, chromatin-associated transcriptional repressor that antagonizes Polycomb group (PcG) function and modulates chromatin structure (PMID:7539744, PMID:25249625). It carries an N-terminal KRAB-like repressor domain (PMID:7539744) and binds double-stranded DNA in a sequence non-specific manner, antagonizing BMI1/EZH2 PcG body formation, derepressing PcG target genes, and lowering H3K27me3 levels through an indirect mechanism that does not alter the composition or stability of PcG complexes (PMID:25249625). In its native form, SSX2 supports tumor cell proliferation but, when ectopically expressed, induces DNA damage, genomic instability, and p53-dependent senescence, the latter requiring the Mediator complex (MED1/MED4/MED14) (PMID:25363656, PMID:31695025). SSX2 also drives context-dependent changes in tumor cell adhesion and dissemination distinct from canonical EMT (PMID:27276714). As the SYT(SS18)-SSX2 oncogenic fusion characteristic of synovial sarcoma, SSX2 contributes a Polycomb-corepressor activity combined with the SS18 SWI/SNF-coactivator activity to deregulate chromatin and gene expression genome-wide, binding preferentially to H3K27me3-marked chromatin (PMID:17018603, PMID:22594313); through this fusion it recruits beta-catenin into a transcriptionally active nuclear complex independent of canonical Wnt signaling (PMID:16462762), destabilizes BMI1 to impair H2A ubiquitination and reactivate PcG targets (PMID:19337376), suppresses the anti-apoptotic genes MCL1 and BCL2A1 via ATF2/TLE1 binding at CRE promoter elements (PMID:22797074), derepresses E-cadherin by sequestering the repressor Slug from its promoter (PMID:16849535), activates EphB2/ephrin-mediated cytoskeletal remodeling (PMID:17686994), and reprograms mesenchymal stem cells toward a neural lineage in part through direct occupancy and upregulation of FGFR2 (PMID:21996728).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 1995 Medium

    Established that SSX2 is likely a transcriptional repressor by identifying a KRAB-like domain, providing the first functional hypothesis for an otherwise uncharacterized protein.

    Evidence Sequence analysis and structural homology identification

    PMID:7539744

    Open questions at the time
    • Domain identification did not demonstrate repressor activity functionally
    • No DNA or chromatin targets defined
  2. 2002 Medium

    Identified the first direct SSX2 protein partners (RAB3IP and SSX2IP) via its N-terminal moiety and showed SSX2 can drive nuclear relocalization of RAB3IP, hinting at a role in protein subcellular distribution.

    Evidence Yeast two-hybrid, GST pull-down, immunofluorescence of transfected cells (single lab)

    PMID:12007189

    Open questions at the time
    • Functional consequence of the interactions not defined
    • Not validated in endogenous tissue context
  3. 2006 Medium

    Defined how the SYT-SSX2 fusion deregulates transcription, showing it recruits beta-catenin to the nucleus independently of Wnt and sequesters the repressor Slug to derepress E-cadherin.

    Evidence Co-IP, ChIP, immunofluorescence, siRNA knockdown, luciferase reporter assays in synovial sarcoma cells

    PMID:16462762 PMID:16849535

    Open questions at the time
    • Single-lab findings
    • Direct vs indirect nature of beta-catenin recruitment not fully resolved
  4. 2006 Medium

    Established the dual coactivator/corepressor logic of the fusion, showing SS18 contributes SWI/SNF association and SSX contributes Polycomb association, both retained in the fusion to deregulate histone modifications and DNA methylation.

    Evidence Conditional expression, microarray, ChIP for histone marks, bisulfite sequencing

    PMID:17018603

    Open questions at the time
    • Mechanism of mark recruitment not resolved
    • Limited to CD44/IGF2 loci
  5. 2007 Medium

    Connected the fusion to a cytoskeletal phenotype, showing SYT-SSX2 activates EphB2/ephrin signaling driving neurite-like remodeling plus an independent microtubule-stabilizing effect.

    Evidence Retroviral transduction, EphB2 blockade rescue, immunofluorescence, patient tissue immunohistochemistry

    PMID:17686994

    Open questions at the time
    • How transcriptional changes link to detyrosinated tubulin accumulation unclear
    • Single lab
  6. 2009 Medium

    Mechanistically linked the fusion to Polycomb antagonism by showing it destabilizes BMI1 and impairs H2A ubiquitination, reactivating PcG target genes.

    Evidence Co-IP, western blot for BMI1 stability, H2A ubiquitination assay, gene expression analysis

    PMID:19337376

    Open questions at the time
    • Mechanism of BMI1 destabilization not defined
    • Direct vs indirect interaction unresolved
  7. 2011 Medium

    Showed SYT-SSX2 imposes a lineage program, directly occupying and upregulating neural genes including FGFR2 to commit mesenchymal progenitors to a pro-neural fate while blocking myogenic/adipogenic differentiation.

    Evidence Retroviral transduction, ChIP, expression profiling, shRNA knockdown with phenotypic rescue

    PMID:21996728

    Open questions at the time
    • Full target gene network not mapped
    • Single lab
  8. 2012 Medium

    Established a druggable apoptotic axis and the genome-wide chromatin preference, showing SS18-SSX2 suppresses MCL1/BCL2A1 via ATF2/TLE1 at CRE elements (sensitizing to ABT-263) and binds predominantly H3K27me3-marked chromatin.

    Evidence ChIP and ChIP-seq, expression analysis, siRNA, cytotoxicity assay, in vivo model, hierarchical clustering

    PMID:22594313 PMID:22797074

    Open questions at the time
    • Determinants of activation vs repression at H3K27me3 sites only partly explained by genomic position
    • Single lab
  9. 2014 Medium

    Characterized native (non-fusion) SSX2 as a non-specific dsDNA-binding chromatin protein that antagonizes PcG function and lowers H3K27me3, while ectopic expression triggers DNA damage, genomic instability, and p53-dependent senescence.

    Evidence PcG body imaging, ChIP for H3K27me3, in vitro DNA-binding, ectopic expression and knockdown, gamma-H2AX, senescence assays

    PMID:25249625 PMID:25363656

    Open questions at the time
    • Indirect mechanism of PcG antagonism not molecularly defined
    • Source of genomic instability not pinpointed
  10. 2016 Medium

    Clarified that SSX2 modulates adhesion and dissemination rather than canonical EMT, with knockdown altering focal adhesion gene expression, invasion, and in vivo tumorigenicity in prostate cancer.

    Evidence Knockdown/overexpression, morphology, expression profiling, invasion and in vivo tumorigenicity assays

    PMID:27276714

    Open questions at the time
    • Direct transcriptional targets for focal adhesion genes not identified
    • Tissue-context dependence unclear
  11. 2019 Medium

    Identified the Mediator complex as a specific effector of SSX2-induced senescence, distinguishing it from oncogene- or chemotherapy-induced senescence pathways.

    Evidence Functional genetic screen, siRNA of MED1/MED4/MED14, senescence assays with specificity controls

    PMID:31695025

    Open questions at the time
    • How SSX2 engages Mediator mechanistically not defined
    • Single lab
  12. 2021 Low

    Reported a distinct cell-biological consequence of SSX2 expression — S-phase-dependent intranuclear lamin bodies independent of its Polycomb or Mediator activities.

    Evidence Immunofluorescence in breast epithelial cells, pharmacological S-phase block, component exclusion (single lab)

    PMID:34808373

    Open questions at the time
    • Mechanism of lamin body formation remains indirect and immunofluorescence-based
    • Functional significance unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • The molecular basis by which native SSX2 reads chromatin and indirectly antagonizes Polycomb, and how this is mechanistically distinct from the fusion-driven program, remains unresolved.
  • No structural model of SSX2 on chromatin
  • No defined sequence-specific or mark-specific recruitment mechanism
  • Native SSX2 partners beyond RAB3IP/SSX2IP largely uncharacterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 4 GO:0003677 DNA binding 1
Localization
GO:0005634 nucleus 3 GO:0005694 chromosome 2
Pathway
R-HSA-4839726 Chromatin organization 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-8953897 Cellular responses to stimuli 2
Partners
ATF2BMI1CTNNB1RAB3IPSNAI2SSX2IPTLE1

Evidence

Reading pass · 16 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1995 SSX2 protein contains an N-terminal domain with homology to the Kruppel-associated box (KRAB), a transcriptional repressor domain previously found only in Kruppel-type zinc finger proteins, establishing SSX2 as a putative transcriptional repressor. Sequence analysis and structural homology identification The EMBO journal Medium 7539744
2002 SSX2 physically interacts with two novel proteins, RAB3IP (human homologue of a Ras-like GTPase Rab3A interactor) and SSX2IP, via its N-terminal moiety; RAB3IP is normally cytoplasmic but co-expression with SSX2 results in its nuclear relocalization; both interactions were confirmed by yeast two-hybrid and GST pull-down assays in vitro. Yeast two-hybrid, GST pull-down, immunofluorescence of transfected cells Genes, chromosomes & cancer Medium 12007189
2006 The SYT-SSX2 fusion protein recruits beta-catenin to the nucleus and forms a transcriptionally active nuclear complex with beta-catenin; depletion of SYT-SSX2 in primary synovial sarcoma cells caused loss of nuclear beta-catenin signal and decreased beta-catenin signaling activity. This nuclear localization was independent of canonical Wnt signaling pathways. Co-immunoprecipitation, immunofluorescence, siRNA knockdown in primary synovial sarcoma cells, luciferase reporter assay Oncogene Medium 16462762
2006 SYT-SSX2 interacts preferentially with the transcriptional repressor Slug (not Snail), preventing Slug from binding the proximal E-cadherin promoter, thereby derepressing E-cadherin transcription; this was shown by co-immunoprecipitation and chromatin immunoprecipitation, and confirmed by luciferase reporter assays showing SYT-SSX2 overcomes Slug-mediated E-cadherin repression. Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), luciferase reporter assay Cancer research Medium 16849535
2006 The SS18-SSX2 fusion protein acts as a transcriptional activator-repressor that induces epigenetic gene deregulation, including altered histone modifications at the CD44 and IGF2 promoters and changes in DNA methylation at the IGF2 imprinting control region; SS18 normally associates with SWI/SNF (coactivator) and SSX associates with polycomb (corepressor), and both activities are retained in the fusion protein. Conditional expression + cDNA microarray profiling, chromatin immunoprecipitation for histone modifications, bisulfite sequencing for DNA methylation Cancer research Medium 17018603
2007 SYT-SSX2 activates the ephrin (Eph/ephrin) signaling pathway, causing cytoskeletal remodeling including cell elongation and neurite-like extensions; blockade of EphB2 signaling reversed this aberrant cytoskeletal phenotype. Additionally, SYT-SSX2 independently stabilizes the microtubule network via accumulation of detyrosinated Glu-tubulin in a manner independent of ephrin signaling. Retroviral transduction, EphB2 blockade rescue experiment, immunofluorescence, immunohistochemistry of patient tissue Molecular biology of the cell Medium 17686994
2009 SYT-SSX2 interacts with the polycomb repressive complex and destabilizes the polycomb subunit Bmi1, resulting in impairment of polycomb-associated histone H2A ubiquitination and reactivation of polycomb target genes. Co-immunoprecipitation, western blot for Bmi1 stability, histone H2A ubiquitination assay, gene expression analysis PloS one Medium 19337376
2011 SYT-SSX2 reprograms mesenchymal stem cells (BMMSCs) and myogenic progenitors by directly occupying and upregulating neural-specific genes, committing cells to a pro-neural lineage while simultaneously impairing myogenic and adipogenic differentiation; FGFR2 was identified as a direct target gene occupied and upregulated by SYT-SSX2, and knockdown of FGFR2 abrogated growth and attenuated the neural phenotype in BMMSCs and synovial sarcoma cells. Retroviral transduction, ChIP, gene expression profiling, shRNA knockdown with phenotypic readout Oncogene Medium 21996728
2012 SS18-SSX2 directly suppresses expression of MCL1 and BCL2A1 anti-apoptotic genes by binding through ATF2 to cyclic AMP response elements (CRE) in their promoters and recruiting TLE1/Groucho, while concurrently increasing BCL2 expression; this pathway suppression renders synovial sarcoma cells sensitive to BH3-peptidomimetic ABT-263. ChIP, gene expression analysis, siRNA knockdown, in vitro cytotoxicity assay, in vivo mouse model Oncogene Medium 22797074
2012 SYT-SSX2 is recruited genome-wide predominantly to Polycomb-modified chromatin enriched with H3K27me3; H3K27me3 is the dominant epigenetic marker associated with SYT-SSX2 binding and gene expression regulation, and activated target genes tend to have SYT-SSX2/H3K27me3 sites within the gene body or near the TSS, while repressed genes show SYT-SSX2/H3K27me3 at long-range. Genome-wide ChIP-seq, epigenetic profiling, hierarchical clustering BMC genomics Medium 22594313
2014 SSX2 is a chromatin-associated protein that antagonizes BMI1 and EZH2 polycomb group (PcG) body formation, derepresses PcG target genes, and negatively regulates H3K27me3 levels in melanoma cells; SSX2 binds double-stranded DNA in a sequence non-specific manner; the antagonism of PcG function occurs through an indirect mechanism (likely modulation of chromatin structure) since SSX2 does not affect the overall composition and stability of PcG complexes. Immunofluorescence for PcG bodies, ChIP for H3K27me3, gene expression analysis, in vitro DNA-binding assay Nucleic acids research Medium 25249625
2014 Ectopic SSX2 expression in melanoma and breast cancer cells causes DNA damage, genomic instability (increased DNA content, enlarged nuclei, DNA double-strand breaks), p53-mediated G1 cell cycle arrest, and late apoptosis/senescence; knockdown of endogenous SSX2 in melanoma cell lines reduced cell growth, demonstrating that SSX2 supports tumor cell proliferation. Ectopic overexpression and siRNA knockdown, flow cytometry, γH2AX immunostaining for DNA damage, β-galactosidase senescence assay Molecular oncology Medium 25363656
2016 SSX2 knockdown in prostate cancer cells resulted in epithelial morphology, increased cell proliferation, increased expression of focal adhesion genes, decreased anchorage-independent growth, increased invasion, and increased in vivo tumorigenicity; overexpression had little effect on morphology. SSX2 does not drive epithelial-to-mesenchymal transition (EMT) in prostate cancer but is involved in focal adhesion loss associated with tumor cell dissemination. Knockdown and overexpression in prostate cancer cell lines, morphological analysis, gene expression profiling, invasion assay, in vivo tumorigenicity assay Oncotarget Medium 27276714
2019 The Mediator complex is essential for SSX2-induced senescence: knockdown of MED1, MED4, and MED14 prevented SSX2-induced senescence in cancer cells, whereas MED1 knockdown did not prevent B-Raf- or Epirubicin-induced senescence, indicating a specific link between Mediator and SSX2-mediated senescence. Functional genetic screen, siRNA knockdown of Mediator subunits, senescence assays (β-galactosidase, morphology), specificity controls Cell death & disease Medium 31695025
2021 Ectopic SSX2 expression induces the formation of a novel type of intranuclear lamin bodies containing both A- and B-type lamins but no other nuclear lamina components; this lamin body formation is dependent on S-phase progression and is independent of SSX2 interactions with polycomb proteins or the Mediator complex. Immunofluorescence in breast epithelial cell lines, pharmacological S-phase block, component exclusion analysis The international journal of biochemistry & cell biology Low 34808373
2009 The C-terminal nuclear localization signal (NLS) of SSX2 is required for its nuclear import; deletion of the NLS prevented nuclear localization and instead SSX2 accumulated in the endoplasmic reticulum in a misfolded state, while NLS-deleted SSX2 was correctly folded and secreted. Heterologous expression in Pichia pastoris, indirect immunofluorescence, deletion mutagenesis Applied microbiology and biotechnology Low 19826807

Source papers

Stage 0 corpus · 61 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1995 Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. The EMBO journal 412 7539744
1996 The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer research 193 8840996
1995 Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. The American journal of pathology 137 7495284
2006 SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer research 95 16849535
2006 The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer research 82 17018603
2015 PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer immunology research 72 26041735
2014 Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 60 24457462
2011 Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2. Oncogene 57 21996728
2006 The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex. Oncogene 57 16462762
2002 The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP. Genes, chromosomes & cancer 54 12007189
2007 Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. The Prostate 42 17929270
2001 Primary synovial sarcoma of the kidney: Report of a case confirmed by molecular detection of the SYT-SSX2 fusion transcripts. Pathology international 39 11422798
2012 SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. Oncogene 34 22797074
2014 Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability. Molecular oncology 33 25363656
2011 Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. Journal of immunotherapy (Hagerstown, Md. : 1997) 32 21904219
2002 Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas. Oncogene 32 12037676
2012 Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2. BMC genomics 31 22594313
2015 β-catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition. Oncotarget 30 26259251
2009 The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1. PloS one 26 19337376
2007 The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway. Molecular biology of the cell 24 17686994
2002 Cryptic t(X;18), ins(6;18), and SYT-SSX2 gene fusion in a case of intraneural monophasic synovial sarcoma. Cancer genetics and cytogenetics 24 12505262
2001 Calcifying/ossifying synovial sarcoma shows t(X;18) with SSX2 involvement and mitochondrial calcifications. Histopathology 24 11207827
2007 Primary monophasic synovial sarcoma of the duodenum with SYT/SSX2 type of translocation. Human pathology 21 17509396
2014 Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. PloS one 19 24681846
2004 Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. International journal of cancer 19 15382048
2014 SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression. Nucleic acids research 18 25249625
2014 SSX2-4 expression in early-stage non-small cell lung cancer. Tissue antigens 17 24645645
2014 Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. Cancer immunology, immunotherapy : CII 17 25078248
2021 Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia. Molecular therapy. Methods & clinical development 16 34729377
2004 Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells. Journal of immunology (Baltimore, Md. : 1950) 16 15153546
2003 Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2. Cancer immunity 16 14677925
2014 DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. Vaccine 15 24492013
2005 Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. Clinical immunology (Orlando, Fla.) 15 15596411
2002 Real-time polymerase chain reaction as an aid for the detection of SYT-SSX1 and SYT-SSX2 transcripts in fresh and archival pediatric synovial sarcoma specimens: report of 25 cases from St. Jude Children's Research Hospital. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 14 12469233
1996 Affinities and intrinsic activities of dopamine receptor agonists for the hD21 and hD4.4 receptors. European journal of pharmacology 14 8773470
2012 Cancer/testis antigen SSX2 enhances invasiveness in MCF-7 cells by repressing ERα signaling. International journal of oncology 13 22344619
2008 Cryptic chromosome rearrangement resulting in SYT-SSX2 fusion gene in a monophasic synovial sarcoma. Cancer genetics and cytogenetics 13 18992642
2011 A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses. Cancer immunology, immunotherapy : CII 12 21630107
2011 Synovial sarcoma of the tongue confirmed by molecular detection of the SYT-SSX2 fusion gene transcript. International journal of surgical pathology 12 22007079
2021 Undifferentiated sarcoma of bone with a round to epithelioid cell phenotype harboring a novel EWSR1-SSX2 fusion identified by RNA-based next-generation sequencing. Genes, chromosomes & cancer 11 34538011
2018 Rab3IP interacts with SSX2 and enhances the invasiveness of gastric cancer cells. Biochemical and biophysical research communications 10 30005870
2018 Antitumor effect of recombinant Mycobacterium smegmatis expressing MAGEA3 and SSX2 fusion proteins. Experimental and therapeutic medicine 10 30186454
2016 SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. Oncotarget 8 27276714
2007 Expression and purification of the cancer antigen SSX2: a potential cancer vaccine. Protein expression and purification 8 17931884
2006 A variant of the SYT-SSX2 fusion gene in a case of synovial sarcoma. Cancer genetics and cytogenetics 8 16682293
2002 A rare synovial sarcoma of the kidney exhibiting translocation (X;18) and SYT-SSX2 fusion gene. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed 8 12201571
2003 SYT-SSX2 variant of primary pulmonary synovial sarcoma with focal expression of CD117 (c-Kit) protein and a poor clinical outcome. Archives of pathology & laboratory medicine 7 12683902
2002 Expression of SSX-2 and SSX-4 genes in neuroblastoma. The International journal of biological markers 6 12521124
2010 Primary pulmonary biphasic synovial sarcoma confirmed by molecular detection of a SYT-SSX2 fusion gene: report of 1 case. The Korean journal of internal medicine 5 20830232
2009 Improved secretion of the cancer-testis antigen SSX2 in Pichia pastoris by deletion of its nuclear localization signal. Applied microbiology and biotechnology 5 19826807
2008 A t(X; 18) SYT-SSX2 positive synovial sarcoma in the pelvis of a young adult male: a rare case report with review of literature. Indian journal of cancer 5 18626152
2004 Are there geographical differences in the frequency of SYT-SSX1 and SYT-SSX2 chimeric transcripts in synovial sarcoma? Cancer detection and prevention 5 15350633
2020 Primary monophasic synovial sarcoma of the cervical esophagus confirmed by detection of the SS18-SSX2 fusion transcripts: case report and literature review. Surgical case reports 4 32691176
2019 A functional genetic screen identifies the Mediator complex as essential for SSX2-induced senescence. Cell death & disease 4 31695025
2012 Primary Monophasic Synovial Sarcoma Arising in the Mesentery: Case Report of an Extremely Rare Mesenteric Sarcoma Confirmed by Molecular Detection of a SYT-SSX2 Fusion Transcript. Korean journal of pathology 4 23109999
2018 Primary Synovial Sarcoma arising from gingivo-buccal sulcus harbouring SS18-SSX2 positive fusion transcript: The 1st reported case in English literature. Journal of stomatology, oral and maxillofacial surgery 3 29325767
2011 [Analysis of SYT/SSX1 and SYT/SSX2 fusion genes from synovial sarcoma]. Molekuliarnaia biologiia 2 22393780
2021 SSX2 promotes the formation of a novel type of intranuclear lamin bodies. The international journal of biochemistry & cell biology 1 34808373
2026 MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay. Blood 0 41662627
2006 Expression of SSX2 tumor antigen in baculovirus expression system and its application for screening of blood serum of melanoma patients. Experimental oncology 0 16837900
2005 [Expression of SSX2 gene in human urologic neoplasms]. Zhonghua wai ke za zhi [Chinese journal of surgery] 0 15854347

Missed literature

Know a paper Affinage missed for SSX2? Flag it for the maintainers and the community.

No submissions yet.